Nodality Announces Data Presentations at 2009 ASH
South San Francisco, CA, November 30, 2009Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, will present seven abstracts at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA (Dec. 4 – 8, 2009). Two submissions are accepted for oral presentation.
Presentations will include research related to Nodality's Single Cell Network Profiling (SCNP) technology applied to acute myeloid leukemia (AML) and other diseases.
AML Abstracts
Researchers will present findings about the use of SCNP for identifying unique characteristics of individual disease cells and predicting patient response to specific therapies.
- Abstract No. 1588: FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations
- Abstract No. 1582: Single Cell Network Profiles in Non-M3 AML Associated with Patient Response to Standard Induction Therapy
- Abstract No. 2745: Distinct Signaling Profiles of Gemtuzumab Ozogamicin Responsiveness and Refractoriness in AML
- Abstract No. 397: SCNP as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure (selected for oral presentation)
- Abstract No. 325: Classification of Acute Myeloid Leukemia (AML) Based On Apoptosis and Myeloid Signaling Networks (selected for oral presentation)
- Abstract No. 3827: SCNP to Evaluate the Mechanism of Action of ON 01910.Nanbsp-A Novel Clinical Trial Stage
- Abstract No. 4531: Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML (published online-only on the ASH abstracts site)
CLL Abstract
Researchers will present data showing the uses of SCNP for characterizing cell networks in Chronic Lymphocytic Leukemia (CLL).
- Abstract No. 1263: Single Cell Profiling of B Cell Receptor Signaling and Apoptosis Networks in Chronic Lymphocytic Leukemia: Association with in Vitro Sensitivity to Fludarabine Monophosphate (F-ara-A)
Nodality is a private, South San Francisco-based biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling technology platform. Through its ability to functionally characterize cell signaling networks at the single cell level of resolution Nodality is committed to the biological characterization of individual patients to optimally match them with biologically-targeted treatments.
About Single Cell Network ProfilingSingle Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signalling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior in single cells, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality is also utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.